<!DOCTYPE html>
<html lang="en">
  <head>
    <meta charset="UTF-8" />
    <meta name="viewport" content="width=device-width, initial-scale=1.0" />
    <title>Page 35</title>

    <link href="tailwind.css" rel="stylesheet" />
    <link href="styles.css" rel="stylesheet" />
    <script src="footer.js" defer></script>
    <style></style>
  </head>
  <body>
    <div
      style="
        background-color: #f2f2f4;
        display: grid;
        grid-template-columns: 1fr 1fr;
        height: 85.5vh;
        /* margin-bottom: -9.5vw; */
      "
    >
      <div
        style="
          background-color: #002068;
          padding: 5vw;
          gap: 0.5vw;
          position: relative;
          z-index: 1;
        "
        class="flex flex-col"
      >
        <div>
          <h1
            class="volta-modern-text font-normal m-0 p-0 w-full text-light"
            style="color: #f2f2f4; font-size: 2.5vw; line-height: 3vw"
          >
            Case Study:<b> South Africa</b>
          </h1>
          <h2
            class="volta-modern-text mt-2 p-0"
            style="
              color: #f2f2f4;
              font-size: 1.3vw;
              font-weight: 100;
              line-height: 1.8vw;
            "
          >
            Leveraging Private Health Insurance to improve access for Sybrava
            <i>(Leqvio)</i>
          </h2>
        </div>
        <div class="mt-6">
          <h3 class="font-bold text-xl text-white">Background</h3>
          <p
            style="
              color: #f2f2f4;
              line-height: 1.5vw;
              font-weight: light !important;
            "
          >
            South Africa Healthcare funding is through public sector for 84$ of
            the population and 16% for PHIs. Access to innovation is mostly
            through PHIs which operate under regulations that require them to at
            east provide certain level of care for a set of conditions including
            hyperlipidemia. The SoC for this condition is statins and Ezetimibe.
            PSK9s are not included in the treatment algorithm but there is an
            opportunity to apply for reimbursement on the basis of clinical and
            economic value of Sybrava.
          </p>
        </div>
        <div class="mt-6">
          <h3 class="font-bold text-xl text-white">Project Goal</h3>
          <p
            style="
              color: #f2f2f4;
              line-height: 1.5vw;
              font-weight: light !important;
            "
          >
            The objective of this project was to obtain reimbursement of Sybrava
            for primary and secondary hyperlipidaemia patients that are not
            reaching treatment goal despite being treated adequately on statins
            and ezetimibe. This required scoping put the PHIs in terms of their
            patient population size and plan (affordability) to identify PHIs
            where there is opportunity to utilise clinical value to obtain
            reimbursement of Sybrava for patients.
          </p>
        </div>
      </div>

      <div
        style="padding: 5vw; gap: 0.5vw"
        class="flex flex-col h-full justify-around"
      >
        <img
          src="./assets/SouthAfrica.png"
          width="80"
          class="absolute top-4 right-4"
        />
        <div class="grid grid-cols-4 gap-4 items-center">
          <div></div>
          <div class="col-span-3">
            <h3 class="font-bold text-xl font-blue">Key Learnings</h3>
          </div>

          <div><img src="./assets/outline01.png" width="100" /></div>
          <div class="col-span-3 pt-2 pb-4 border-bottom-light-blue">
            <div class="font-bold font-blue">
              Understanding PHI's Objectives and Challenges
            </div>
            <p class="font-blue">
              While Sybrava has a lot of clinical value for patients that are
              inadequately controlled on SoC, it is important to build your
              value proposition using the PHI's unmet needs to tailor make your
              product's value to those challenges (mostly economic challenges).
            </p>
          </div>

          <div><img src="./assets/outline02.png" width="100" /></div>
          <div class="col-span-3 pt-2 pb-4 border-bottom-light-blue">
            <div class="font-bold font-blue">Stakeholder Engagement</div>
            <p class="font-blue">
              Market shaping by engaging all stakeholders that have an influence
              on PHI decision making (KOLs, regulators, societies, etc) to drive
              the change in how the disease state is currently managed, what
              gaps still exist to influence guidelines change to support the use
              of new products.
            </p>
          </div>

          <div><img src="./assets/outline03.png" width="100" /></div>
          <div class="col-span-3 pt-2 pb-4">
            <div class="font-bold font-blue">Quantifying Value</div>
            <p class="font-blue">
              Though we have great evidence on Sybrava impact, we did not
              quantify the economic value that using Sybrava would bring
              considering the high cost difference between Sybrava and SoC.
            </p>
          </div>
        </div>
      </div>
    </div>
    <site-footer
      style="position: relative; z-index: 100"
      next-text="Next (Project Details)"
      next-href="page-36.html"
    ></site-footer>
  </body>
</html>
